866-997-4948(US-Canada Toll Free)

Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Jul 2017

Category :

Pharmaceutical

No. of Pages : 49 Pages

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Pipeline Review, H2 2017

Summary

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. The latest report Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H2 2017, outlays comprehensive information on the Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Glutamate receptor subunit epsilon-2 or N-methyl D-aspartate receptor subtype 2B (NMDAR2B or NR2B) is a protein encoded by the GRIN2B gene. It is mediated by glycine. It acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them resulting in an irreversible neuronal death. The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 5, 1 and 1 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Dermatology which include indications Major Depressive Disorder, Treatment Resistant Depression, Acute Ischemic Stroke, Brain Ischemia, Burns, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Epilepsy, Myocardial Infarction, Neurodegenerative Diseases, Neuropathic Pain, Subarachnoid Hemorrhage, Traumatic Brain Injury and Traumatic Spinal Cord Injury.

Furthermore, this report also reviews key players involved in Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B)
- The report reviews Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Overview 6
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Therapeutics Assessment 12
Assessment by Mechanism of Action 12
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Companies Involved in Therapeutics Development 17
BioCrea GmbH 17
Bristol-Myers Squibb Company 17
Cerecor Inc 18
Evotec AG 18
Johnson & Johnson 19
Luc Therapeutics Inc 19
NeurOp Inc 20
UCB SA 20
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Drug Profiles 21
EVT-100 Series - Drug Profile 21
ifenprodil - Drug Profile 22
JNJ-0808 - Drug Profile 23
Neu-2000 - Drug Profile 24
NP-10679 - Drug Profile 26
NP-11948 - Drug Profile 28
radiprodil - Drug Profile 29
rislenemdaz - Drug Profile 31
Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated with Schizophrenia - Drug Profile 34
Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder - Drug Profile 36
Small Molecules to Antagonize NR2B for Neuropathic Pain - Drug Profile 37
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Dormant Products 38
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Discontinued Products 39
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Product Development Milestones 40
Featured News & Press Releases 40
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by BioCrea GmbH, H2 2017
Pipeline by Bristol-Myers Squibb Company, H2 2017
Pipeline by Cerecor Inc, H2 2017
Pipeline by Evotec AG, H2 2017
Pipeline by Johnson & Johnson, H2 2017
Pipeline by Luc Therapeutics Inc, H2 2017
Pipeline by NeurOp Inc, H2 2017
Pipeline by UCB SA, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017

List of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *